INNOVATIVE SOLUTIONS
A Growing Pipeline of Innovative Drug Candidates for Immune-Mediated Inflammation.
AltruBio has built a differentiated niche pipeline for antibody-targeted therapy with products at various stages of development.
A Growing Pipeline of Innovative Drug Candidates for Immune-Mediated Inflammation.
AltruBio has built a differentiated niche pipeline for antibody-targeted therapy with products at various stages of development.
AbGn-168H Neihulizumab
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase II
Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase II
Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with leiolizumab.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Renal Transplantation Non-Human Primate preclinical studies ongoing.
AbGn-268 Leiolizumab
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Preclinical
Potency improved version of AbGn-168H for Chronic Inflammatory Disease
Mar, 2020
AltruBio
top